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ABSTRACT
Donor T cells activated by recipient alloantigens cause graft-versus-host disease (GVHD) after hematopoietic
cell transplantation. Activated T cells express CD25, among other components of the interleukin-2 receptor.
We conducted a phase I/II study to determine whether administration of CD25-specific antibody conjugated
to ricin toxin A could reduce the risk of grade III or IV GVHD after marrow transplantation from HLA-
matched unrelated donors. All patients received methotrexate and cyclosporine after the transplantation. The
immunotoxin was given to 36 patients for 4 consecutive days beginning approximately 36 hours after the
marrow infusion was completed. Fourteen (40%) of the 35 patients who could be evaluated developed grade
III or IV GVHD. In a contemporaneous population of 121 patients who received marrow from HLA-matched
unrelated donors and were given methotrexate and cyclosporine without the immunotoxin, the incidence of
grades III and IV GVHD was 24%. Cyclosporine blocked the induction of CD25 expression on alloactivated
T cells in vitro but had no detectable effect on CD25 expression by T-regulatory cells. Taken together, these
results are consistent with the hypothesis that cyclosporine protected alloactivated donor T cells from the
effects of the immunotoxin, whereas the CD25 T-regulatory cells remained susceptible, causing an unex-
pected exacerbation of acute GVHD.
© 2004 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Donor T cells that recognize recipient alloanti-
ens initiate graft-versus-host disease (GVHD) after
arrow transplantation [1]. Within 24 to 48 hours
fter the transplantation, these cells express certain
olecules, or activation antigens, that are not present
n the surface of resting T cells. Central features of
his activation process are the expression of receptors
2] for interleukin (IL)-2 and the secretion [3] of IL-2.
he IL-2 receptor is composed of 3 well-character-
zed polypeptide chains termed  (CD25), , and 
4]. High-afﬁnity receptors for IL-2 are formed by
oncovalent dimerization of the  and  chains, o
52hereas the  chain is responsible for signal transduc-
ion. Resting T cells do not express high-afﬁnity re-
eptors for IL-2.
Several studies have been performed to evaluate
he administration of CD25-speciﬁc monoclonal an-
ibodies (mAbs) in vivo for the treatment or preven-
ion of GVHD [5-10]. Treatment with either murine
r humanized CD25-speciﬁc mAb was well tolerated
n patients with GVHD, and the improvement ob-
erved in some patients suggested that the treatment
ad an immunosuppressive effect [5,6]. In further
tudies, however, we found that GVHD could not be
revented by early posttransplantation administration
f either the murine or humanized mAb [7,8]. Labo-
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CD25-Specific Immunotoxin for Prevention of GVHD
Batory studies showed that CD25 cells obtained from
ecipients after engraftment were saturated with mAb.
n some recipients, humanized antibody-coated cells
ersisted in the circulation for as long as 90 days after
he transplantation. This indicates that the treatment
id not eliminate alloactivated donor T cells. We
ypothesized that this failure to eliminate CD25
ells accounted for the inability of mAb treatment to
revent GVHD.
Engert et al. [11] have developed a CD25-speciﬁc
mmunotoxin (IT) with highly potent killing activity
gainst activated T cells. This IT is composed of the
D25-speciﬁc murine immunoglobulin G1 mAb
FT5 linked to deglycosylated ricin toxin A (dgRTA)
ia the sterically hindered heterobifunctional di-
ulﬁde linker SMPT [4-succinimidyl-oxycarbonyl-
-methyl--(2-pyridyldithio)-toluene]. Use of the
MPT linker in this IT confers greater stability in
ivo than is seen with other more labile heterobifunc-
ional linkers, and destruction of terminating mannose
nd fucose residues from ricin toxin A decreases he-
atic clearance [12-14]. As a consequence, this IT has
uch-improved pharmacokinetic behavior compared
ith other ricin-based ITs. The 50% inhibitory con-
entration of RFT5-dgRTA is less than 10 ng/mL
hen tested in assays that measure 3H-leucine or
H-thymidine incorporation in mitogen- or alloanti-
en-activated human T cells. In this phase I/II study,
e evaluated the use of RFT5-dgRTA for prevention
f GVHD after marrow transplantation from HLA-
atched unrelated donors.
ATERIALS AND METHODS
atient and Donor Selection
The institutional review board approved the pro-
ocol and consent form, and all patients included in
he study consented to participate. Patients between
8 and 55 years of age with acute leukemia, chronic
yeloid leukemia, lymphoma, or chronic lymphocytic
eukemia with HLA-matched unrelated donors were
ligible. Patients were ineligible if they had received
rior marrow or peripheral blood cell transplants or if
hey had had prior radiotherapy with exposures
1500 cGy to the chest or abdomen or any radiother-
py to the chest or abdomen within 6 months before
he transplantation. Patients were excluded if they had
ardiac, pulmonary, hepatic, or renal abnormalities
hat were likely to increase transplant-related mortal-
ty. Patients with severe or life-threatening infection
ere also excluded.
HLA-A and -B antigens of donors and recipients
ere typed by serologic methods. HLA-C antigens
ere typed by serology or by sequence-speciﬁc prim-
ng methods. HLA-DRB1 and -DQB1 alleles were
yped by DNA hybridization with sequence-speciﬁc w
B&MTligonucleotide probes [15,16]. Patients with HLA-A,
B, -C, -DRB1, and -DQB1-matched unrelated do-
ors were eligible, and unrelated donor/recipient pairs
ith any HLA-A, -B, -C, -DRB1, or -DQB1 mis-
atching were excluded.
Pretransplantation serum samples were screened
or the presence of antibody against murine immuno-
lobulin, and patients with a positive test result were
xcluded from the study. Patients who developed an
ncrease of aspartate aminotransferase to3 times the
pper limit of normal during the conditioning regi-
en were excluded. Likewise, those who developed an
ncrease in serum creatinine to more than twice the
pper limit of normal, veno-occlusive disease of the
iver (as indicated by a serum bilirubin concentration
2 mg/dL), 2.5% weight gain above baseline, or
xygen saturation 90% on the day after the trans-
lantation were excluded.
ransplantation Procedures and Supportive Care
Patients were given 60 mg of cyclophosphamide
er kilogram body weight for 2 days, followed by 12.0
y of total body irradiation (TBI) administered in
.0-Gy fractions twice daily or 13.2 to 14.4 Gy of TBI
dministered in 1.2-Gy fractions 3 times daily. Intra-
hecal methotrexate was given for prevention of cen-
ral nervous system malignancy, and local ﬁeld irradi-
tion was given for prevention of testicular relapse in
atients at risk of these complications. Cyclosporine
CSP) and methotrexate were given for GVHD pro-
hylaxis [17]. Patients were hospitalized in rooms with
igh-efﬁciency particulate air-ﬁltered air and positive-
ressure ventilation. Antibiotics were used for preven-
ion of bacterial, Candida species [18], cytomegalovi-
us [19,20], herpes simplex virus, and Pneumocystis
arinii infections. Marrow was aspirated by conven-
ional methods at the donor center and transported to
he Fred Hutchinson Cancer Research Center (Seat-
le, WA) according to procedures of the National
arrow Donor Program (Minneapolis, MN). Patients
ith major AB blood group incompatibility had
lasma exchange before the transplantation, and
lasma depletion of the marrow was used for manage-
ent of minor AB blood group incompatibility. Mar-
ow was infused through a central venous catheter
fter the last TBI treatment on day 0.
erum Levels of RFT5-dgRTA
Concentrations of intact RFT5-dgRTA in the
lood were measured by a radioimmunoassay as de-
cribed previously [21]. Blood samples were obtained
mmediately before each infusion; at 4 and 8 hours
fter the start of each infusion; and at 16, 24, and 48
ours after the start of the last infusion. Elimination
alf-lives and areas under the curve were analyzed
ith the PKCALC program [22].
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5ixed Lymphocyte Cultures
Responder peripheral blood mononuclear cells
PBMC) from an HLA-A2-positive healthy volunteer
ere ﬁltered though nylon wool to enrich T cells.
ultures were established in round-bottomed 96-well
lates with 1.0  105 responder cells and 1.0  105
rradiated (33 Gy) allogeneic PBMCs from an HLA-
2-negative donor in 200 L of RPMI-1640 medium
ontaining 15% pooled human serum and graded con-
entrations of CSP. At speciﬁed times, cells were
tained with a phycoerythrin-conjugated murine mAb
peciﬁc for human CD25 (BD Biosciences, San Jose,
A), a ﬂuorescein isothiocyanate-conjugated murine
Ab speciﬁc for HLA-A2 (BD Biosciences), and
-amino-actinomycin D. Cells were ﬁxed in 3% for-
alin and analyzed with the use of a FACScan ﬂow
ytometer (BD Biosciences).
For secondary proliferative assays, responder and
rradiated stimulator PBMCs (40-50 106 each) were
rst cultured together in 50-mL conical-bottomed
est tubes for 10 days in medium with or without CSP
00 ng/mL. On day 4, an aliquot from each culture
as labeled with phycoerythrin-conjugated mouse
nti-human CD25-speciﬁc mAb, and another aliquot
as left unlabeled. All 4 fractions were incubated with
uper-paramagnetic beads coated with murine mAb
peciﬁc for phycoerythrin (Miltenyi Biotec, Auburn,
A) and then passed through a magnetic column
MidiMACS LS; Miltenyi) under conditions opti-
ized for depletion of CD25 cells. Cells in the
ow-through fraction from each column were then
aintained in the original medium until day 10. Re-
ponder cells (5  104) were then cultured in round-
ottomed 96-well plates with irradiated stimulator
BMCs (5 104) in 200 L of medium without CSP.
roliferation was determined on successive days by
H-thymidine incorporation.
linical Trial Design, End Points, and Statistical
nalysis
The study was designed before data were available
o demonstrate an association between HLA-DQB1
ismatching and the risk of GVHD [15]. From ret-
ospective analysis of previous results at the Fred
utchinson Cancer Research Center, it was estimated
hat patients with acute leukemia would have a 48%
isk of grade III or IV GVHD after marrow transplan-
ation from HLA-A, -B, or -DRB1-matched unrelated
onors when methotrexate and CSP were given for
rophylaxis and that patients with chronic myeloid
eukemia would have a 38% risk (unpublished data).
he study was later amended to exclude patients with
LA-DQB1 mismatching before any such patients
ere enrolled. The goals of this phase I/II study were
o identify a dose of RFT5-dgRTA for which the risk
f grade III or IV GVHD was 15% to 25% and the I
54ncidence of grade III toxicity related to the IT was
20%, with no grade IV toxicity.
The CD25-speciﬁc IT RFT5-dgRTA was pre-
ared according to previously described methods [11]
nd tested under an Investigational New Drug appli-
ation from the Food and Drug Administration.
FT5-dgRTA was given as a 4-hour infusion each day
or 4 consecutive days beginning at approximately 36
ours after the marrow infusion was completed. Dose
evel 1 was 0.25 mg/m2/d, and dose level 2 was 0.75
g/m2/d. Three higher doses were included in the
tudy design but were not tested. Patients were ini-
ially enrolled at dose level 2. The study was con-
ucted in 2 phases: the ﬁrst focused on identifying an
ppropriate dose of RFT5-dgRTA for the study, and
he second focused on estimating the activity of
FT5-dgRTA. During both phases of the study, dose
evels were to be decreased whenever there was an
xcessive incidence of toxicity attributed to the drug,
nd dose levels were to be increased whenever there
as an excessive incidence of grade III or IV GVHD.
uring the ﬁrst phase of the study, a decrease to the
ext lower dose was triggered whenever any patient
eveloped grade 4 toxicity or any 4 of 4 to 8 patients
eveloped grade 3 toxicity, and an increase to the next
igher dose was triggered whenever any patient de-
eloped unequivocal evidence of grade III or IV acute
VHD. The ﬁrst phase of the study ended and the
econd phase began when no trigger for decreasing or
ncreasing the dose was reached after 8 patients were
nrolled at a given dose.
During the second phase of the study, a decrease
o the next lower dose was triggered whenever any
atient developed grade 4 toxicity or any 4 of 4 to 10,
of 12 to 14, or 6 of 16 to 20 patients developed grade
toxicity. An increase to the next higher dose was
riggered whenever 4 of 4 to 9, 5 of 11 to 12, 6 of 14
o 16, or 7 of 18 to 20 patients developed unequivocal
vidence of grade III or IV GVHD. The study was
erminated when no trigger for decreasing or increas-
ng the dose was reached after 20 patients were en-
olled at any given dose. Patients who died or had
ecurrent malignancy before day 50 without toxicity
r grade III or IV GVHD were replaced by other
atients for consideration of dose escalation or de-
scalation. To preserve the continuity of enrollment,
ecisions regarding changes of dose level and termi-
ation of the study were made on the basis of infor-
ation available at the time, with no requirement for
aiting to determine outcome in all previously en-
olled patients.
A complete description of a similar study design
as been published previously [23,24]. From simula-
ions with 2 different hypothetical favorable scenarios
oncerning the relationship between the RFT5-
gRTA dose and the risks of toxicity and grade III or
V GVHD, we estimated that the study design had a
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CD25-Specific Immunotoxin for Prevention of GVHD
B% to 6% probability of leading to an erroneous
onclusion that no satisfactory dose could be found
hen one existed. With the favorable scenarios tested,
here was an 85% to 97% chance that the study design
ould correctly identify a dose for which the risks of
oxicity and grade III or IV GVHD met the desired
peciﬁcations. With 2 different hypothetical unfavor-
ble scenarios, there was a 56% to 70% chance of
eaching a correct conclusion that there was no dose
hat met the desired speciﬁcations. The study was
pen for enrollment between September 1996 and
eptember 1999. Survival data were analyzed as of
ovember 2003.
ESULTS
nrollment
The ﬁrst patient enrolled in the study was treated
ith RFT5-dgRTA 0.75 mg/m2/d for 4 consecutive
ays beginning on day 2 after the transplantation
dose level 2). This patient developed nonoliguric re-
al failure and hyperkalemia on day 6 after the trans-
lantation, had dialysis on 2 occasions, and recovered
ormal renal function within 5 days. The next patients
eceived RFT5-dgRTA 0.25 mg/m2/d (dose level 1).
one of these patients experienced grade 3 or 4 tox-
city, and none experienced unequivocal grade III or
V GVHD. Therefore, the ﬁrst phase of the study was
oncluded, and the second phase of the study was
tarted at dose level 1. None of the ﬁrst 4 patients
nrolled in the second phase of the study experienced
rade 3 or 4 toxicity, but all 4 developed grade III or
V GVHD. Subsequently, 23 patients were enrolled at
ose level 2. As discussed below, one of these patients
ould not be evaluated for GVHD. As allowed by the
tudy design, this patient was replaced for the pur-
oses of analyzing the GVHD end point, and the last
patients were enrolled while results were still pend-
ng from the other 20 patients enrolled at dose level 2
uring the second phase of the study (Table 1).
oxicity
All patients received the full dose of RFT5-dgRTA,
s prescribed by the protocol. None of the patients
eveloped any acute toxicity that required prolongation
f the infusion, interruption of the infusion, reduction of
he dose, or discontinuation of treatment. None of the
atients developed dyspnea, wheezing, vascular leak syn-
rome (VLS), hypertension, or expressive aphasia. The
atient with renal failure had a transient increase of the
erum creatine kinase concentration to 1056 U/L (upper
imit of normal, 190) on day 6 after the transplantation,
ut myoglobin was not detected in the urine. No other
atients had clinical or laboratory evidence of myositis or
habdomyolysis as a result of treatment with RFT5-
gRTA. 2
B&MTharmacokinetics of RFT5-dgRTA
The median peak and trough serum concentra-
ions of RFT5-dgRTA among patients treated at dose
evel 1 were 51 ng/mL (range, 16-75 ng/mL) and 8
g/mL (range, 0-19 ng/mL). Only 3 of the 11 patients
ested at dose level 1 had mean trough serum concen-
rations 10 ng/mL. The median peak and trough
erum concentrations of RFT5-dgRTA among pa-
ients treated at dose level 2 were 201 ng/mL (range,
3-325 ng/mL) and 51 ng/mL (range, 16-146 ng/mL).
raft-versus-Host Disease
One of the 24 patients enrolled at dose level 2 was
ot evaluated for the development of acute GVHD,
ecause CSP prophylaxis was stopped on day 16 after
he transplantation to induce a graft-versus-leukemia
ffect when blasts were identiﬁed in the blood. Ten
43%) of the remaining 23 patients enrolled at dose
evel 2 developed grade III or IV GVHD. Thirty-four
97%) of the 35 patients who could be evaluated de-
eloped grade II to IV GVHD (Table 2), and 14
40%) developed grade III or IV GVHD. Stage 3 or 4
kin GVHD was diagnosed in 29 (83%) patients.
tage 2 to 4 liver GVHD was diagnosed in 13 (37%)
atients, and stage 2 to 4 gastrointestinal GVHD was
iagnosed in 3 (9%) patients. Seventeen (65%) of the
able 1. Characteristics of Patients, According to the Dose
f RFT5-dgRTA
Characteristic
Dose 1
(n  12)
Dose 2
(n  24)
Total (%)
(n  36)
atient age (n)
10-19 y 0 0 0 (0)
20-29 y 2 2 4 (11)
30-39 y 4 3 7 (19)
40-49 y 2 15 17 (47)
50-59 y 4 4 8 (22)
edian patient age (y) 40 46 46
ge range (y) 27-54 23-55 23-55
onor/recipient sex (n)
Female/female 1 6 7 (19)
Female/male 3 4 7 (19)
Male/female 5 5 10 (28)
Male/male 3 9 12 (33)
isease risk category (n)*
Low 4 12 16 (44)
Intermediate 7 10 17 (47)
High 1 2 3 (8)
otal body irradiation (n)
12 Gy 6 14 20 (56)
13.2 Gy 6 10 16 (44)
The low-risk category includes chronic myeloid leukemia (CML)
in chronic phase (n 	 16). The intermediate-risk category in-
cludes CML in accelerated phase (n 	 5), acute leukemia in
remission (n 	 11), and chronic lymphocytic leukemia (n 	 1).
The high-risk category includes CML in blast crisis (n 	 1) and
acute leukemia in relapse (n 	 2).6 patients who survived beyond day 100 after the
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5ransplantation developed clinical extensive chronic
VHD.
urvival and Recurrent Malignancy
The median follow-up time from the transplanta-
ion to the date of last contact for surviving patients at
he time of analysis was 56 months (range, 21.5-76.4
onths). Nineteen (53%) of the patients have died.
he most frequent causes of death were infection and
ecurrent malignancy (data not shown). Proven or
robable invasive Aspergillus or Zygomycetes species in-
ections of the lung were diagnosed in 5 patients, and
ystemic Candida species infection was diagnosed in 4
atients. GVHD was a contributing cause of death in
0 patients. Malignancy recurred in 2 (13%) of 16
atients with diseases in the low-risk category, in 2
13%) of 16 patients with diseases in the intermediate-
isk category, and in 2 (50%) of 4 patients with dis-
ases in the high-risk category.
ermination of the Trial
Given the incidence of grade III to IV GVHD
mong the 22 patients who could be evaluated after
nrollment at dose level 2 in the second phase of the
tudy, the original design would have allowed escala-
ion of the dose of RFT5-dgRTA to 1.25 mg/m2/d
dose level 3). Unexpectedly, the incidence of grade III
able 2. GVHD Stages and Grades in Patients, According to the
ose of RFT5-dgRTA*
Organ
Stage or
grade
Dose 1
(n  12)
Dose 2
(n  23)†
Total (%)
(n  35)†
kin stage 0 1 1 2 (6)
1 0 0 0 (0)
2 0 4 4 (11)
3 11 17 28 (80)
4 0 1 1 (3)
iver stage 0 4 9 13 (37)
1 4 5 9 (26)
2 2 6 8 (23)
3 0 2 2 (6)
4 2 1 3 (9)
ut stage 0 2 5 7 (20)
1 10 15 25 (71)
2 0 2 2 (6)
3 0 0 0 (0)
4 0 1 1 (3)
verall grade 0 1 0 1 (3)
I 0 0 0 (0)
II 7 13 20 (57)
III 3 9 12 (34)
IV 1 1 2 (6)
Data indicate the numbers (percentages) of patients in each cate-
gory.
One other patient was not evaluated because the administration of
cyclosporine was stopped on day 16 after the transplantation to
induce a graft-versus-leukemia effect.nd IV GVHD was only 24% in a contemporaneous C
56opulation of 121 patients who received methotrexate
nd CSP after marrow transplantation from unrelated
onors with the same HLA-matching criteria but who
id not participate in this study. Patients who received
FT5-dgRTA were signiﬁcantly older and had more
dvanced malignancy than the 121 who received only
SP and methotrexate. After adjustment for these
ifferences, the comparison of grade III and IV
VHD between the 2 groups was not statistically
igniﬁcant (odds ratio, 1.9; 95% conﬁdence interval,
.8-4.4; P	 .12), but the comparison of grade II to IV
VHD was signiﬁcant (odds ratio, 8.7; 95% conﬁ-
ence interval, 1.1-70.6; P 	 .04). Despite the differ-
nce in risk of GVHD, there was no signiﬁcant dif-
erence in survival between the 2 groups before or
fter adjustment for patient age and disease risk. Al-
hough these comparisons were not prespeciﬁed as
art of the original study design, the interim results
uggested that administration of the CD25-speciﬁc IT
ould have exacerbated the severity of GVHD, rather
han decreasing the incidence of grade III to IV
VHD, as we had originally expected. We therefore
lected to terminate the study in the interest of patient
afety.
uppression of CD25 Expression by CSP
To account for the unexpectedly high incidence of
VHD in this study, we considered the possibility
hat CSP might have prevented the inducible expres-
ion of CD25 by donor T cells that recognize recip-
ent alloantigens without affecting the constitutive ex-
ression of CD25 by regulatory T cells. With the use
f CSP for posttransplantation immunosuppression,
reatment with RFT5-dgRTA could have deleted reg-
latory T cells while having minimal effects on cells
hat initiate GVHD. To test this possibility, mixed
ymphocyte cultures were performed in the presence
f graded concentrations of CSP, and cells were ana-
yzed for expression of CD25.
In the whole-cell population, the effect of CSP
as most easily detected on day 5. CSP reduced the
roportion of blasts in the cultures, most noticeably
n day 5. In the absence of CSP, the culture contained
pproximately 35% blasts (Figure 1A), whereas the
ulture treated with CSP 400 ng/mL contained ap-
roximately 10% blasts (Figure 1B). In the absence of
SP, the culture contained approximately 60%
D25 cells, whereas CSP-treated cultures contained
0% to 30% CD25 cells (Figure 1D). The reduction
n CD25 expression was detected in the “bright” sub-
et. With CSP 400 ng/mL, only approximately 2% of
he cells were CD25-bright. The proportion of
D25-dull cells was unaffected by CSP and remained
onstant at approximately 15%. Results were qualita-
ively similar on day 4 (Figure 1C). In the absence of
SP, 90% of the blasts on day 5 were CD25-bright,
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CD25-Specific Immunotoxin for Prevention of GVHD
Bnd 10% were CD25-dull (Figure 1F). As the concen-
ration of CSP was increased, the proportion of
D25-bright blasts decreased, whereas the proportion
f CD25-dull blasts increased. With CSP 400 ng/mL,
nly 10% to 15% of the blasts were CD25-bright, and
0% were CD25-dull. Results were qualitatively sim-
lar on day 4 (Figure 1E).
roliferative Response after Removing CD25
ells
Further experiments were performed to determine
he functional effects of depleting CD25 cells from
ixed lymphocyte cultures. For this purpose, cultures
ere established in the absence or presence of CSP
400 ng/mL), and CD25 cells were depleted by neg-
tive immunomagnetic selection on day 4. Controls
ere sham-depleted without the CD25-speciﬁc anti-
ody. Cells were then cultured in the original medium
igure 1. Cyclosporine suppresses the expression of CD25 by
esponder cells in mixed lymphocyte culture. Responder cells were
istinguished from stimulator cells with the use of an informative
LA marker, and dead cells were gated out by staining with 7-ami-
o-actinomycin D. Panels A and B show forward light scatter and
D25 staining for cells cultured in the absence (A) or presence (B)
f cyclosporine (400 ng/mL) on day 5. The vertical line indicates
he distinction between blasts and nonactivated cells, and the hor-
zontal lines indicate the distinctions among the CD25, CD25-
ull, and CD25-bright populations. The percentages of CD25-
right (}) and CD25-dull (Œ) cells were analyzed on days 4 (C and
) and 5 (D and F) both in the whole population (C and D) and
eparately in blasts identiﬁed by high forward light scatter (E and F).
anels C and D also display the total percentage of CD25 cells
), whereas panels E and F display the percentage of blasts () in
he cultures.ith or without CSP until day 10. Cells were then t
B&MTested in secondary mixed lymphocyte cultures in the
bsence of CSP. When CSP was absent from the
rimary culture, CD25 depletion had no detectable
ffect on the secondary proliferative response com-
ared with sham-depleted controls (Figure 2A). When
SP was present in the primary culture, CD25 deple-
ion increased the secondary proliferative response
ompared with sham-depleted controls (Figure 2B).
hese results conﬁrmed that the cells expressing
D25 in primary cultures containing CSP had a reg-
latory function.
ISCUSSION
Under in vivo conditions, unprimed T cells begin
o proliferate within 48 hours after adoptive transfer
n major histocompatibility complex-disparate recipi-
nts, and proliferation reaches a peak within 4 to 5
ays and decreases thereafter [25]. Responses show
aster kinetics with primed cells than with unprimed
ells. In this study, RFT5-dgRTA was administered
n days 1 to 4 after transplantation to encompass the
nticipated timing of CD25 expression after donor
ells have ﬁrst encountered alloantigen in the recipi-
nt, regardless of whether these cells have a naive or
ross-reactive memory phenotype. The dose and
chedule of IT administration were designed to sus-
ain plasma concentrations of RFT5-dgRTA at more
han the 50% inhibitory concentration throughout
his period. This pharmacokinetic result was achieved
or most patients treated at dose level 2 (0.75 mg/
2/d) but not for those treated at dose level 1 (0.25
g/m2/d). We were unable to determine whether
reatment with RFT5-dgRTA actually accomplished
he intended pharmacodynamic effect of depleting
onor T cells that expressed CD25 after recognizing
ecipient alloantigens, because very few donor lym-
hocytes can be detected during the ﬁrst week after
ransplantation.
igure 2. Depletion of CD25 cells on day 4 from a mixed lym-
hocyte culture in the presence of cyclosporine increased the sec-
ndary proliferative response. Cultures were maintained in the
bsence (A) or presence (B) of cyclosporine (400 ng/mL) and were
epleted of CD25 cells () or were sham-depleted (}). Secondary
roliferative responses were tested in the absence of cyclosporine.
ata indicate the mean 
 SEM 3H-thymidine incorporation in
riplicate cultures.
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5ITs made with dgRTA have a characteristic tox-
city proﬁle that includes VLS manifested as edema
nd weight gain, and muscle damage manifested as
yalgia, myopathy, or rhabdomyolysis [21,26-30].
e did not see evidence of VLS in any of the patients
ho participated in this trial, most likely because the
oses of IT were low in comparison to those tested in
ther studies. We strongly suspect, however, that the
ccurrence of severe, transient renal impairment in 1
atient was caused by treatment with RFT5-dgRTA,
ecause of the close temporal relationship between the
dministration of the drug and the onset of renal
ysfunction and because no other cause of renal im-
airment could be identiﬁed. Renal dysfunction might
ave been related to subclinical rhabdomyolysis, but
aboratory ﬁndings characteristic of myoglobin-in-
uced nephropathy were absent.
We found no evidence that the incidence of grade
II and IV acute GVHD was reduced by the admin-
stration of RFT5-dgRTA according to the regimens
ested in this study. The results of this study are
imilar to those of a previous study that demonstrated
42% conditional probability (equivalent to a 37%
robability according to the methods used in this
tudy) of grade III to IV GVHD among patients who
eceived methotrexate and CSP after marrow trans-
lantation from HLA-A, -B, -C, -DRB1, and -DQB1-
atched unrelated donors in our center between 1985
nd 1995 [15]. We subsequently observed an unex-
ectedly lower incidence of grade III and IV GVHD
mong patients who received the same prophylactic
egimen after marrow transplantation from HLA-
atched unrelated donors between 1996 and 1999,
hen this study was open for enrollment. During this
nterval, 24% of the 121 HLA-matched unrelated
arrow transplant recipients who did not receive
FT5-dgRTA developed grade III or IV GVHD, and
2% developed grade II to IV GVHD.
Administration of the IT could have exacerbated
VHD by eliminating CD25-regulatory (T-regula-
ory) cells [31-33]. In 1995, Sakaguchi et al. [34] ﬁrst
eported that inoculation of congenic wild-type
D25 CD4 cells into immunodeﬁcient mice of
usceptible strains can cause autoimmune inﬂamma-
ory changes in the stomach. Immunodeﬁcient recip-
ents reconstituted with CD25-depleted lymphocytes
lso demonstrated accelerated rejection of allogeneic
kin grafts. Injection of CD25 CD4 T-regulatory
ells together with the CD25 population prevented
he development of autoimmunity and ablated the
cceleration of skin graft rejection. Subsequent in
itro studies have indicated that CD25 CD4 T-
egulatory cells suppress immune responses through
ontact-dependent mechanisms [35-37], and in vivo
tudies have indicated that these cells prevent autoim-
une inﬂammatory changes through production of
ransforming growth factor- [38,39] and IL-10 c
5840,41], although suppression can occur in the absence
f signals mediated by transforming growth factor-
42]. The CD25 CD4 T-regulatory cells are func-
ionally distinct from the CD25 CD4 alloreactive
opulation, but the 2 populations have similar cell-
urface markers.
Taylor et al. [43,44] recently reported that CD25
D4 T-regulatory cells can regulate GVHD in
ice. CD4 cells primed in vitro against a recipient
ajor histocompatibility complex class II alloantigen
aused acute GVHD after adoptive transfer into sub-
ethally irradiated mice. The CD4 cells did not cause
VHD if cells had been primed in the presence of a
o-stimulatory blockade mediated by antibodies either
gainst CD80 and CD86 or against CD154 (CD40
igand). The CD4 cells, however, did cause GVHD
f the CD25 subpopulation had been removed before
riming in the presence of a co-stimulatory blockade
43]. Further studies showed that GVHD in mice was
xacerbated by removal of CD25 CD4 T-regula-
ory cells from the graft and was ameliorated by add-
ng large numbers of in vitro-activated CD25CD4
-regulatory cells to the graft [44]. The severity of
VHD was also exacerbated by depletion of CD25
ells in the recipient before the transplantation [44].
Within the past 3 years, CD25 CD4 T-regula-
ory cells have been demonstrated in humans, but
vidence to support the role of these cells in control-
ing GVHD in humans has not been previously re-
orted [45-49]. The results of our in vitro experiments
howed that CSP blocks the induction of CD25 ex-
ression on alloactivated T cells but has no detectable
ffect on CD25 expression by T-regulatory cells. In
articular, CSP prevented the appearance of CD25-
right cells but had no apparent effect on CD25-dull
ells after allogeneic stimulation in vitro. In previous
tudies, we have detected CD25 on T cells from mar-
ow transplant recipients who were treated with CSP
7], but correlations between CD25 expression and
SP levels have not been carefully analyzed. On the
asis of our in vitro results, however, we propose that
n the presence of CSP, the level of CD25 expression
n GVHD effector cells was too low to permit sus-
eptibility to the IT, whereas CSP-resistant CD25-
right T-regulatory cells remained susceptible, result-
ng in an unexpected exacerbation of acute GVHD.
Ex vivo treatment with RFT5-dgRTA has been
sed to deplete donor T cells activated by recipient
LA alloantigens in mixed lymphocyte cultures [50].
n vivo infusion of treated cells did not cause GVHD
nd was associated with accelerated immune reconsti-
ution in some patients. The exacerbation of GVHD
bserved with in vivo administration of RFT5-dgRTA
id not occur with T cells treated after activation by
ecipient alloantigens ex vivo. Chen et al. [51] re-
orted that the addition of a humanized CD25-spe-
iﬁc antibody to a posttransplantation immunosup-
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Bressive regimen containing CSP seemed to improve
esults after HLA-haploidentical marrow transplanta-
ion, but all patients developed GVHD that was
eadily controlled by glucocorticoid treatment. Nearly
ll randomized clinical trials testing the use of IL-2
eceptor antagonists in renal allograft recipients have
ncluded concomitant treatment with a calcineurin
nhibitor [52]. Our current results suggest that the
utcomes in these clinical settings might be improved
y withholding CSP during the administration of a
D25-speciﬁc agent. Future studies will be needed to
etermine whether the use of CD25- or IL-2 recep-
or-speciﬁc agents without concomitant administra-
ion of a calcineurin inhibitor can prevent GVHD
fter allogeneic hematopoietic cell transplantation.
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